Novel benzyl-benzimidazolyl derivatives as inhibitors of tyrosine kinases,particularly TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR, for the treatment oftumors, according to formula (I), wherein the radicals R1, R2, r and s aredefinedaccording to Claim (1).